Jose Allongo
Internal Medicine · Loxahatchee, FLNPI 1568496685
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by Boehringer Ingelheim at 41.1% of the total. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 11 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$80
- Lilly USA, LLC$45
- Kvk-tech, Inc.$28
- Johnson & Johnson$27
- GSK$15
Across 101 payments — averaging $9483.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$429K
- Eli Lilly$414K
- Sanofi US Services Inc.$71K
- AbbVie$22K
- Genentech, Inc.$19K
- Avanir Pharmaceuticals, Inc.$3K
What the payments were for
- Food & beverage$9348%
- Education$10252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 4 | $80 |
| Lilly USA, LLC | 1 | $45 |
| Kvk-tech, Inc. | 4 | $28 |
| Johnson & Johnson | 1 | $27 |
| GSK | 1 | $15 |
How this compares
$194 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $108,052 |
| JardianceEmpagliflozin | 77 | $94,869 |
| EliquisApixaban | 90 | $89,176 |
| FarxigaDapagliflozin Propanediol | 72 | $53,253 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $25,900 |
| TrulicityDulaglutide | 20 | $25,176 |
| XareltoRivaroxaban | 20 | $22,881 |
| MounjaroTirzepatide | 21 | $22,432 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $10,901 |
| SynthroidLevothyroxine Sodium | 54 | $6,571 |
| PremarinEstrogens, Conjugated | 18 | $4,997 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $4,353 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $4,208 |
| Atorvastatin Calcium | 543 | $3,648 |
| Rosuvastatin Calcium | 379 | $3,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $80 | $105,77092 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $45 | $47,60741 claims |
| Johnson & JohnsonXarelto | $27 | $22,88120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Loxahatchee
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.